Skip to main content
NCBI home page
Clinical Molecular Pathology logoLink to Clinical Molecular Pathology
. 1996 Dec;49(6):M331–M339. doi: 10.1136/mp.49.6.m331

Inhibitors of collagenase but not of gelatinase reduce cartilage explant proteoglycan breakdown despite only low levels of matrix metalloproteinase activity

Carol J Brown 1,2, Shamim Rahman 1,2, Allison C Morton 1,2, Claire L Beauchamp 1,2, Helena Bramwell 1,2, David J Buttle 1,2
PMCID: PMC408083  PMID: 16696099

Abstract

Aims—To investigate the level of matrix metalloproteinase activity during the time-course of cartilage explant proteoglycan breakdown; to determine the effects of selective small-molecule inhibitors of matrix metalloproteinases on proteoglycan degradation.

Methods—The levels of matrix metalloproteinase activity in cartilage explant cultures and conditioned media were monitored by use of a quenched fluorescent substrate. The constants for inhibition of certain matrix metalloproteinases by a series of synthetic inhibitors were determined. Bovine and human cartilage explant cultures were treated with interleukin-1, tumor necrosis factor or retinoic acid and the amount of proteoglycan released into the culture medium in the absence and presence of the inhibitors was quantified. Control experiments, examining the inhibition of other proteinases, and investigating possible toxic or non-specific effects of the inhibitors, were carried out.

Results—The profile of inhibition of proteoglycan release suggested the involvement of interstitial collagenase-like, rather than gelatinase- or possibly stromelysin-like, proteinases. No evidence was found for toxic or non-specific mechanisms of inhibition. Very low levels of activity of the known matrix metalloproteinases were present during the time-course of aggrecan breakdown.

Conclusions—A novel collagenase-like proteinase(s) may be involved in cartilage proteoglycan breakdown. Gelatinase-type matrix metalloproteinases do not seem to be involved in this process. Specific collagenase inhibitors may be therapeutically efficacious in the treatment of arthritis.

Keywords: cartilage

Keywords: proteoglycan breakdown

Keywords: proteases

Full text

PDF
M331

Images in this article

M336Image
on p.M336

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan J. A., Hembry R. M., Angal S., Reynolds J. J., Murphy G. Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain. J Cell Sci. 1991 Aug;99(Pt 4):789–795. doi: 10.1242/jcs.99.4.789. [DOI] [PubMed] [Google Scholar]
  2. Andrews H. J., Edwards T. A., Cawston T. E., Hazleman B. L. Transforming growth factor-beta causes partial inhibition of interleukin 1-stimulated cartilage degradation in vitro. Biochem Biophys Res Commun. 1989 Jul 14;162(1):144–150. doi: 10.1016/0006-291x(89)91974-8. [DOI] [PubMed] [Google Scholar]
  3. Andrews H. J., Plumpton T. A., Harper G. P., Cawston T. E. A synthetic peptide metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage in vitro. Agents Actions. 1992 Sep;37(1-2):147–154. doi: 10.1007/BF01987904. [DOI] [PubMed] [Google Scholar]
  4. Barrett A. J. Human cathepsin B1. Purification and some properties of the enzyme. Biochem J. 1973 Apr;131(4):809–822. doi: 10.1042/bj1310809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bird T. A., Gearing A. J., Saklatvala J. Murine interleukin-1 receptor: differences in binding properties between fibroblastic and thymoma cells and evidence for a two-chain receptor model. FEBS Lett. 1987 Dec 10;225(1-2):21–26. doi: 10.1016/0014-5793(87)81124-9. [DOI] [PubMed] [Google Scholar]
  6. Bode W., Gomis-Rüth F. X., Stöckler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett. 1993 Sep 27;331(1-2):134–140. doi: 10.1016/0014-5793(93)80312-i. [DOI] [PubMed] [Google Scholar]
  7. Buttle D. J., Handley C. J., Ilic M. Z., Saklatvala J., Murata M., Barrett A. J. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum. 1993 Dec;36(12):1709–1717. doi: 10.1002/art.1780361210. [DOI] [PubMed] [Google Scholar]
  8. Buttle D. J., Saklatvala J., Barrett A. J. The inhibition of interleukin 1-stimulated cartilage proteoglycan degradation by cysteine endopeptidase inactivators. Agents Actions Suppl. 1993;39:161–165. doi: 10.1007/978-3-0348-7442-7_18. [DOI] [PubMed] [Google Scholar]
  9. Buttle D. J., Saklatvala J. Lysosomal cysteine endopeptidases mediate interleukin 1-stimulated cartilage proteoglycan degradation. Biochem J. 1992 Oct 15;287(Pt 2):657–661. doi: 10.1042/bj2870657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Buttle D. J., Saklatvala J., Tamai M., Barrett A. J. Inhibition of interleukin 1-stimulated cartilage proteoglycan degradation by a lipophilic inactivator of cysteine endopeptidases. Biochem J. 1992 Jan 1;281(Pt 1):175–177. doi: 10.1042/bj2810175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Campbell M. A., Handley C. J. The effect of retinoic acid on proteoglycan biosynthesis in bovine articular cartilage cultures. Arch Biochem Biophys. 1987 Mar;253(2):462–474. doi: 10.1016/0003-9861(87)90200-1. [DOI] [PubMed] [Google Scholar]
  12. Caputo C. B., Sygowski L. A., Wolanin D. J., Patton S. P., Caccese R. G., Shaw A., Roberts R. A., DiPasquale G. Effect of synthetic metalloprotease inhibitors on cartilage autolysis in vitro. J Pharmacol Exp Ther. 1987 Feb;240(2):460–465. [PubMed] [Google Scholar]
  13. Cawston T. E., Barrett A. J. A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem. 1979 Nov 1;99(2):340–345. doi: 10.1016/s0003-2697(79)80017-2. [DOI] [PubMed] [Google Scholar]
  14. Cawston T. E., Galloway W. A., Mercer E., Murphy G., Reynolds J. J. Purification of rabbit bone inhibitor of collagenase. Biochem J. 1981 Apr 1;195(1):159–165. doi: 10.1042/bj1950159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cawston T. E., Murphy G. Mammalian collagenases. Methods Enzymol. 1981;80(Pt 100):711–722. doi: 10.1016/s0076-6879(81)80054-7. [DOI] [PubMed] [Google Scholar]
  16. Cawston T. Blocking cartilage destruction with metalloproteinase inhibitors: a valid therapeutic target? Ann Rheum Dis. 1993 Nov;52(11):769–770. doi: 10.1136/ard.52.11.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cole A. A., Chubinskaya S., Schumacher B., Huch K., Szabo G., Yao J., Mikecz K., Hasty K. A., Kuettner K. E. Chondrocyte matrix metalloproteinase-8. Human articular chondrocytes express neutrophil collagenase. J Biol Chem. 1996 May 3;271(18):11023–11026. doi: 10.1074/jbc.271.18.11023. [DOI] [PubMed] [Google Scholar]
  18. Davies B., Brown P. D., East N., Crimmin M. J., Balkwill F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993 May 1;53(9):2087–2091. [PubMed] [Google Scholar]
  19. Dayer J. M., Bréard J., Chess L., Krane S. M. Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. J Clin Invest. 1979 Nov;64(5):1386–1392. doi: 10.1172/JCI109596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dean D. D., Martel-Pelletier J., Pelletier J. P., Howell D. S., Woessner J. F., Jr Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest. 1989 Aug;84(2):678–685. doi: 10.1172/JCI114215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Farndale R. W., Buttle D. J., Barrett A. J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta. 1986 Sep 4;883(2):173–177. doi: 10.1016/0304-4165(86)90306-5. [DOI] [PubMed] [Google Scholar]
  22. Flannery C. R., Lark M. W., Sandy J. D. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem. 1992 Jan 15;267(2):1008–1014. [PubMed] [Google Scholar]
  23. Florentin D., Sassi A., Roques B. P. A highly sensitive fluorometric assay for "enkephalinase," a neutral metalloendopeptidase that releases tyrosine-glycine-glycine from enkephalins. Anal Biochem. 1984 Aug 15;141(1):62–69. doi: 10.1016/0003-2697(84)90425-1. [DOI] [PubMed] [Google Scholar]
  24. Fosang A. J., Last K., Knäuper V., Neame P. J., Murphy G., Hardingham T. E., Tschesche H., Hamilton J. A. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J. 1993 Oct 1;295(Pt 1):273–276. doi: 10.1042/bj2950273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Fosang A. J., Last K., Neame P. J., Murphy G., Knäuper V., Tschesche H., Hughes C. E., Caterson B., Hardingham T. E. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. Biochem J. 1994 Dec 1;304(Pt 2):347–351. doi: 10.1042/bj3040347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Fosang A. J., Neame P. J., Hardingham T. E., Murphy G., Hamilton J. A. Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. J Biol Chem. 1991 Aug 25;266(24):15579–15582. [PubMed] [Google Scholar]
  27. Fosang A. J., Neame P. J., Last K., Hardingham T. E., Murphy G., Hamilton J. A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem. 1992 Sep 25;267(27):19470–19474. [PubMed] [Google Scholar]
  28. Freije J. M., Díez-Itza I., Balbín M., Sánchez L. M., Blasco R., Tolivia J., López-Otín C. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 1994 Jun 17;269(24):16766–16773. [PubMed] [Google Scholar]
  29. Gullberg U., Lantz M., Lindvall L., Olsson I., Himmler A. Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain. Eur J Cell Biol. 1992 Aug;58(2):307–312. [PubMed] [Google Scholar]
  30. Handley C. J., Buttle D. J. Assay of proteoglycan degradation. Methods Enzymol. 1995;248:47–58. doi: 10.1016/0076-6879(95)48006-4. [DOI] [PubMed] [Google Scholar]
  31. Hughes C., Murphy G., Hardingham T. E. Metalloproteinase digestion of cartilage proteoglycan. Pattern of cleavage by stromelysin and susceptibility to collagenase. Biochem J. 1991 Nov 1;279(Pt 3):733–739. doi: 10.1042/bj2790733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Hutchinson N. I., Lark M. W., MacNaul K. L., Harper C., Hoerrner L. A., McDonnell J., Donatelli S., Moore V., Bayne E. K. In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin-1 beta. Arthritis Rheum. 1992 Oct;35(10):1227–1233. doi: 10.1002/art.1780351016. [DOI] [PubMed] [Google Scholar]
  33. Ilic M. Z., Handley C. J., Robinson H. C., Mok M. T. Mechanism of catabolism of aggrecan by articular cartilage. Arch Biochem Biophys. 1992 Apr;294(1):115–122. doi: 10.1016/0003-9861(92)90144-l. [DOI] [PubMed] [Google Scholar]
  34. Kempson G. E., Muir H., Swanson S. A., Freeman M. A. Correlations between stiffness and the chemical constituents of cartilage on the human femoral head. Biochim Biophys Acta. 1970 Jul 21;215(1):70–77. doi: 10.1016/0304-4165(70)90388-0. [DOI] [PubMed] [Google Scholar]
  35. Kempson G. E., Tuke M. A., Dingle J. T., Barrett A. J., Horsfield P. H. The effects of proteolytic enzymes on the mechanical properties of adult human articular cartilage. Biochim Biophys Acta. 1976 May 28;428(3):741–760. doi: 10.1016/0304-4165(76)90205-1. [DOI] [PubMed] [Google Scholar]
  36. Knight C. G., Willenbrock F., Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263–266. doi: 10.1016/0014-5793(92)80300-6. [DOI] [PubMed] [Google Scholar]
  37. Knäuper V., López-Otin C., Smith B., Knight G., Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem. 1996 Jan 19;271(3):1544–1550. doi: 10.1074/jbc.271.3.1544. [DOI] [PubMed] [Google Scholar]
  38. Lohmander L. S., Neame P. J., Sandy J. D. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993 Sep;36(9):1214–1222. doi: 10.1002/art.1780360906. [DOI] [PubMed] [Google Scholar]
  39. MacNaul K. L., Chartrain N., Lark M., Tocci M. J., Hutchinson N. I. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem. 1990 Oct 5;265(28):17238–17245. [PubMed] [Google Scholar]
  40. Martel-Pelletier J., Cloutier J. M., Pelletier J. P. In vivo effects of antirheumatic drugs on neutral collagenolytic proteases in human rheumatoid arthritis cartilage and synovium. J Rheumatol. 1988 Aug;15(8):1198–1204. [PubMed] [Google Scholar]
  41. Murphy G. J., Murphy G., Reynolds J. J. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett. 1991 Sep 2;289(1):4–7. doi: 10.1016/0014-5793(91)80895-a. [DOI] [PubMed] [Google Scholar]
  42. Murphy G., Cockett M. I., Stephens P. E., Smith B. J., Docherty A. J. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J. 1987 Nov 15;248(1):265–268. doi: 10.1042/bj2480265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Murphy G., Cockett M. I., Ward R. V., Docherty A. J. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J. 1991 Jul 1;277(Pt 1):277–279. doi: 10.1042/bj2770277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Murphy G., Hembry R. M., Reynolds J. J. Characterization of a specific antiserum to rabbit stromelysin and demonstration of the synthesis of collagenase and stromelysin by stimulated rabbit articular chondrocytes. Coll Relat Res. 1986 Oct;6(4):351–363. doi: 10.1016/s0174-173x(86)80005-x. [DOI] [PubMed] [Google Scholar]
  45. Nixon J. S., Bottomley K. M., Broadhurst M. J., Brown P. A., Johnson W. H., Lawton G., Marley J., Sedgwick A. D., Wilkinson S. E. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. Int J Tissue React. 1991;13(5):237–241. [PubMed] [Google Scholar]
  46. Piquilloud Y., Reinharz A., Roth M. Studies on the angiotensin converting enzyme with different substrates. Biochim Biophys Acta. 1970 Apr 22;206(1):136–142. doi: 10.1016/0005-2744(70)90090-2. [DOI] [PubMed] [Google Scholar]
  47. Poole A. R., Hembry R. M., Dingle J. T. Cathepsin D in cartilage: the immunohistochemical demonstration of extracellular enzyme in normal and pathological conditions. J Cell Sci. 1974 Jan;14(1):139–161. doi: 10.1242/jcs.14.1.139. [DOI] [PubMed] [Google Scholar]
  48. Rawlings N. D., Barrett A. J. Evolutionary families of metallopeptidases. Methods Enzymol. 1995;248:183–228. doi: 10.1016/0076-6879(95)48015-3. [DOI] [PubMed] [Google Scholar]
  49. Rich D. H., Brown M. A., Barrett A. J. Purification of cathepsin B by a new form of affinity chromatography. Biochem J. 1986 May 1;235(3):731–734. doi: 10.1042/bj2350731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986 Aug 7;322(6079):547–549. doi: 10.1038/322547a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sandy J. D., Flannery C. R., Neame P. J., Lohmander L. S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest. 1992 May;89(5):1512–1516. doi: 10.1172/JCI115742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Sandy J. D., Neame P. J., Boynton R. E., Flannery C. R. Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. J Biol Chem. 1991 May 15;266(14):8683–8685. [PubMed] [Google Scholar]
  53. Sellers A., Reynolds J. J., Meikle M. C. Neutral metallo-proteinases of rabbit bone. Separation in latent forms of distinct enzymes that when activated degrade collagen, gelatin and proteoglycans. Biochem J. 1978 May 1;171(2):493–496. doi: 10.1042/bj1710493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Stefanovic-Racic M., Stadler J., Georgescu H. I., Evans C. H. Nitric oxide and energy production in articular chondrocytes. J Cell Physiol. 1994 May;159(2):274–280. doi: 10.1002/jcp.1041590211. [DOI] [PubMed] [Google Scholar]
  55. Taylor D. J., Whitehead R. J., Evanson J. M., Westmacott D., Feldmann M., Bertfield H., Morris M. A., Woolley D. E. Effect of recombinant cytokines on glycolysis and fructose 2,6-bisphosphate in rheumatoid synovial cells in vitro. Biochem J. 1988 Feb 15;250(1):111–115. doi: 10.1042/bj2500111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Tyler J. A. Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem J. 1985 May 1;227(3):869–878. doi: 10.1042/bj2270869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Woessner J. F., Jr Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol. 1995;248:510–528. doi: 10.1016/0076-6879(95)48033-1. [DOI] [PubMed] [Google Scholar]
  58. Yocum S. A., Lopresti-Morrow L. L., Gabel C. A., Milici A. J., Mitchell P. G. Bafilomycin A1 inhibits IL-1-stimulated proteoglycan degradation by chondrocytes without affecting stromelysin synthesis. Arch Biochem Biophys. 1995 Feb 1;316(2):827–835. doi: 10.1006/abbi.1995.1111. [DOI] [PubMed] [Google Scholar]
  59. Zhang D., Botos I., Gomis-Rüth F. X., Doll R., Blood C., Njoroge F. G., Fox J. W., Bode W., Meyer E. F. Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d). Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8447–8451. doi: 10.1073/pnas.91.18.8447. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES